Loading stock data…
CORT
$51.42+4.90 (+10.53%)
Market ClosedLast close May 1
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Corcept Therapeutics Incorporated in the Healthcare sector is trading at $51.42. The stock is currently 43% below its 52-week high of $91.00, remaining 15.3% below its 200-day moving average. Technical signals show overbought RSI of 79 and bullish MACD crossover, explaining why CORT maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 79) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$51.42
Potential Downside
61%
Whystock Fair Value$20.03
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$70.40+36.9%
Range$44.00 – $110.00
Fundamentals
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.00B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
56.79
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.63%
Volume
Today's trading volume
3.16M
Recent News
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Lifyorli and rising Korlym demand reshape growth trajectory.
Corcept Therapeutics Inc (CORT) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
Corcept Therapeutics Inc (CORT) reports increased revenue and FDA approval for LIFYORLI, despite facing a net loss and operational hurdles.
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of -1.11% and -4.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics Q1 Earnings Call Highlights
Corcept Therapeutics (NASDAQ:CORT) reported first-quarter 2026 revenue of $164.9 million, up from $157.2 million in the prior-year period, and raised its full-year 2026 revenue guidance to a range of $950 million to $1.05 billion. The company also reported a net loss of $31.8 million for the quarter
Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million. On the other hand, the company’s full-year revenue guidance of $1 billion at the midpoint came in 7.2% above analysts’ estimates. Its GAAP loss of $0.30 per share was significantly below analysts’ consensus estimates.